Ankylosing spondylitis
Therapeutic area
Immunology
Rare disease
Yes
- Definition
- An autoimmune chronic inflammatory disorder characterized by inflammation in the vertebral joints of the spine and sacroiliac joints. It predominantly affects young males. Patients present with stiffness and pain in the spine.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Ankylosing spondylitis
- Therapeutic area
- Immunology
- ankylosing spondylitis
- ankylosing spondylarthritis
- Disease mechanisms
- Inflammatory
- Severity
- Moderate
- Immunology
- Rheumatology
- MONDO ID
- MONDO:0005306
- Parent condition
- MONDO:0003937
Related records
Broader conditions (22)
- Arthritic joint disease
- Arthropathy
- Autoimmune disease
- Autoimmune disorder of musculoskeletal system
- Bone disorder
- Bone inflammation disease
- Connective tissue disorder
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Human disease
- Immune system disorder
- Inflammatory disease
- Musculoskeletal system disorder
- Rheumatic disorder
- Rheumatoid arthritis
- Skeletal system disorder
- Spondylitis
- Spondyloarthropathy
- Vertebral column disorder
Narrower conditions (2)
- Juvenile ankylosing spondylitis
- Juvenile spondyloarthropathy
Trials (511)
- 15-Hydroxyprostaglandin Dehydrogenase in Osteoarthritis and Ankylosing Spondylitis
- 16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis
- 16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
- 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis
- 16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients
- 16.0040 Ankylosing Spondylitis Study
- 2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis
- 99m-Technetium- Glucosamine in Arthritis
- 99mTc-rhAnnexin V-128 a Phase I/IIa Study in Patients With Rheumatoid Arthritis (RA) or Ankylosing Spondylitis (AS)
- 99mTc-rhAnnexin V-128 in Diagnosis of Spondyloarthritis
- A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis ( ProAct )
- A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
- A Clinical Study of JS005 in Patients With Ankylosing Spondylitis
- A Clinical Study With Adalimumab Biosimilar
- A Clinimetric Test of Spinal Sensors in Measuring Spinal Mobility in Axial Spondyloarthritis
- A LONGITUDINAL OBSERVATIONAL STUDY to EVALUATE the EFFICACY of MOVEMENT and IMPLEMENT CONCRETE MOVEMENT RECOMMENDATIONS with the HELP of MOBILITY TRACKING with SMARTWATCHES in SUBJECTS with AXIAL SPONDYLOARTHRITIS
- A Molecule Basic Study of Early Warning for New Pathogenic Risk of Ankylosing Spondylitis
- A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta
- A Multicenter Registry of Adalimumab in Chinese Adult Patients With Active Ankylosing Spondylitis
- A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
Approved drugs (16)
- Adalimumab
- Celecoxib
- Certolizumab pegol
- Dexamethasone
- Dexamethasone sodium phosphate
- Esomeprazole magnesium
- Etanercept
- Golimumab
- Indomethacin
- Infliximab
- Isopropyl alcohol
- Naproxen
- Naproxen sodium
- Prednisolone
- Prednisone
- Secukinumab
Drugs in development (36)
- Abatacept Phase 2
- Aglatimagene besadenovec Phase 2
- Apremilast Phase 3
- ARRY-797 Phase 2
- Bimekizumab Phase 3
- Brodalumab Phase 3
- Diclofenac Phase 3
- Etoricoxib Phase 3
- Filgotinib Phase 3
- Gamcemetinib Phase 2
- Gumokimab Phase 3
- Ivarmacitinib sulfate Phase 3
- Ixekizumab Phase 3
- Izokibep Phase 2
- Meloxicam Phase 3
- Methotrexate Phase 3
- Methylprednisolone Phase 2
- Misoprostol Phase 3
- Mufemilast Phase 2
- Namilumab Phase 2
Other linked drugs (3)
- Dexibuprofen
- Meclofenamic acid
- Naproxen etemesil